EV-A71病毒样颗粒疫苗兔重复肌注非临床安全性评价
该研究在兔中评价候选手足口病EV-A71病毒样颗粒(VLP)疫苗的局部与全身效应,按n+1方案给予超过人用全剂量两倍以上的三剂肌注(混合Alhydrogel佐剂)。接种耐受良好,未见明显毒性,可诱导针对VP1、VP0、完整VLP及不同亚基因型EV-A71的特异性抗体,后续剂量后抗体滴度升高且单因素方差分析有统计学意义;血清IL-6未见测试物相关变化,注射部位炎症指标在恢复期基本逆转。
要点
- 兔按n+1方案肌注三剂EV-A71 VLP疫苗(超人用全剂量两倍以上),耐受良好且未见明显毒性。
- 可诱导针对VP1、VP0、完整VLP及不同亚基因型EV-A71病毒的特异性抗体。
- 后续剂量后EV-A71特异性抗体滴度升高,单因素方差分析显示有统计学意义。
核心结论
- 兔重复肌注EV-A71 VLP疫苗局部和全身耐受良好且具免疫原性,支持该疫苗的临床开发。
研究设计与样本
- 在兔中开展非临床安全性评价,按n+1推荐方案给予三剂混合Alhydrogel佐剂的肌注疫苗,剂量超过人用全剂量两倍以上并加一剂。
主要发现
- 接种耐受良好,所观察各项参数均无明显示毒性征象。
- 可检测到与病毒衣壳蛋白VP1和VP0、完整VLP及与疫苗不同亚基因型EV-A71病毒特异性反应的抗体。
- 后续剂量后观察到EV-A71特异性抗体滴度升高的加强效应,单因素方差分析显示有统计学意义。
- 每两周肌注未引起以血清IL-6升高定义的免疫毒性变化,多数动物整个研究期间IL-6浓度低于定量下限。
- 末次接种后立即处死动物可见注射部位炎症指标升高,但恢复期结束时基本逆转,未记录到提示全身或迟发毒性的发现。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A candidate hand, foot, and mouth disease vaccine comprising of human enterovirus A71 (EV-A71) virus-like particles (VLPs) was tested in rabbits to evaluate the potential local and systemic effects of this vaccine. The rabbits received more than double the full human dose and one additional dose according to the n + 1 recommended scheme. The three doses were given mixed with Alhydrogel adjuvant as intramuscular (IM) injections. Vaccinations were well-tolerated, with no indication of overt toxicity in any parameter observed. An EV-A71 specific immune response in the form of antibodies that specifically reacted with the virus capsid proteins VP1 and VP0, the complete VLP, and EV-A71 viruses of different subgenotypes to that of the vaccine could be demonstrated. A boosting effect in the form of higher EV-A71 specific antibody titers was observed after the subsequent doses, and these enhanced titers were shown to be statistically significant in one-way ANOVA analyses. Fortnightly intramuscular administration of EV-A71 VLP vaccine did not result in any test article-related changes in immunotoxicity as defined by increased serum IL-6, and in general IL-6 concentrations remained below the lower limit of quantitation for the majority of animals throughout the study. Although increased indicators of inflammation at the injection site were observed in animals sacrificed immediately after the last vaccination, these largely reversed at the end of the recovery phase. No findings suggestive of systemic or delayed toxicity were recorded in this independently conducted study. In conclusion, repeated IM administration of the EV-A71 VLP vaccine were locally and systemically well-tolerated in rabbits and immunogenic, supporting the clinical development of the vaccine.
引用
- Salmons B, Lim PY, Djurup R, et al. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine. 2018. PMID: 30293762. doi:10.1016/j.vaccine.2018.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。